Le Lézard
Classified in: Health
Subject: FDA

Maxx Orthopedics Announces US FDA Approval of Freedom® Ultra-Congruent Liner Option Ahead of American Academy of Orthopaedic Surgeons (AAOS) Meeting

NORRISTOWN, Pa., March 7, 2019 /PRNewswire-PRWeb/ -- Maxx Orthopedics, Inc. a subsidiary of Maxx Medical, Pvt. Ltd., a rapidly expanding global orthopedics device company, today announced that it has received US FDA clearance for its Freedom® Ultra-Congruent liner, the latest addition to its Freedom Knee® System.

The Freedom® Ultra-Congruent Liner (UC) was developed with the desire to achieve a higher level of constraint than typically achieved in a traditional cruciate-retaining (CR) knee design. The UC tibial liner includes a deep anterior patellar cut-out to allow for tendon clearance, a prominent anterior lip that aids in prevention of anterior subluxation of the femur, and a prominent posterior lip that assists in resisting posterior translation of the femur. Providing patients with more precise balance and stability, the thickness offerings for the Freedom® Ultra-Congruent Liner will be 1mm increments throughout the size range.

"We are thrilled to add the UC liner offering to our Freedom® Knee System. In addition to the unique design of the Ultra-Congruent liner, we are also introducing new liner thicknesses to help our customers better match the Freedom Knee to the needs of the individual patient. This is an evolutionary step towards our goal of creating and providing solutions that best fit our patients' needs so they, along with our medical professionals, continue to have the best possible outcomes." said Ashesh Shah, CEO, Maxx Medical.

Launched in 2009, The Freedom Knee® System is a total knee replacement system specifically engineered for high flexion, bone conservation and advanced component size and fit capabilities. Maxx will be displaying The Freedom® Ultra-Congruent Liner at AAOS Annual Meeting, March 13-15, in Las Vegas, NV (Booth #2063). For additional information, please visit http://www.maxxortho.com.

About Maxx Medical
Maxx Medical Pvt. Ltd. ("Maxx Medical") develops and markets innovative orthopedic medical devices on an international scale. The company is focused on providing state-of-the-art implants and related solutions that best restore patient mobility while accommodating lifestyle, anatomical and economic needs. Maxx Medical is the parent company of Maxx Orthopedics, Inc., the manufacturer of the Freedom Knee® System and Libertas® Total Hip System.


SOURCE Maxx Orthopedics

These press releases may also interest you

at 03:25
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Deferasirox Film-Coated Tablets, 90 mg and 360 mg, a therapeutically equivalent...

at 03:00
Dr. Scott Howell, a 2019 graduate of Trident University International's (Trident) Ph.D. in Health Sciences program, recently published research on the health benefits of coconut oil in the 7 November 2019 edition of Progress in Cardiovascular...

at 02:08
Biovica, active in cancer diagnostics, today announced that Henrik Winther was appointed SVP Business Development and will be part of the management team. He most recently comes from the role of SVP Precision Diagnostics at Immunovia. "Henrik...

at 02:00
BC Platforms, a world leader in genomic data management and analytics, today announced that it has formed a partnership with Life & Brain Genomics, a division of Life & Brain GmbH. Life & Brain Genomics is one of the leading European service...

at 01:05
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced, following discussions with the U.S. Food and Drug Administration (FDA), that a partial clinical hold effective immediately, for the pediatric population under the age of 14 was...

5 déc 2019
Health Canada is aware that some metformin products available outside Canada have been found to contain a nitrosamine impurity, N-nitrosodimethylamine (NDMA), above the acceptable limit. Metformin is a prescription drug used to control high blood...

News published on 7 march 2019 at 14:00 and distributed by: